Please assess the completion status of the following clinical trial:

Trial Title: Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Major Inclusion Criteria:~1. Males and females between 18 and 75 years of age, inclusive~2. Diagnosis of narcolepsy according to ICSD-3 or DSM-5 criteria~3. Body mass index from 18 to \<45 kg/m2~4. Consent to use a medically acceptable method of contraception~5. Willing and able to provide written informed consent~Major Exclusion Criteria:~1. Female subjects who are pregnant, nursing, or lactating~2. Moderate or severe sleep apnea on the baseline PSG.~3. Any other clinically relevant medical, behavioral, or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness~4. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria~5. History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy, safety, PK assessments, or the ability of the subject to complete the trial per the judgment of the Investigator~6. History of bariatric surgery within the past year or a history of any gastic bypass procedure~7. Presence or history of significant cardiovascular disease~8. Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness~9. Use of any medications that could affect the evaluation of cataplexy~10. Received an investigational drug in the past 30 days or five half-lives (whichever is longer)~11. Previous exposure to or participation in a previous clinical trial of JZP-110 (ADX-N05, R228060, YKP10A)~12. History of phenylketonuria (PKU) or history of hypersensitivity to phenylalanine-derived products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 75 mg of JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- 150 mg JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- 300 mg of JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- Placebo (Type: PLACEBO_COMPARATOR): Once Daily Dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).